These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

13123 related articles for article (PubMed ID: 10804294)

  • 1. Biodistribution of boron concentration on melanoma-bearing hamsters after administration of p-, m-, o-boronophenylalanine.
    Hiratsuka J; Yoshino K; Kondoh H; Imajo Y; Mishima Y
    Jpn J Cancer Res; 2000 Apr; 91(4):446-50. PubMed ID: 10804294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective uptake of para-boronophenylalanine increases in amelanotic melanoma cells transfected by the tyrosinase gene.
    Hiratsuka J; Kondoh H; Tsuboi T; Yoshino K; Imajo Y; Mishima Y
    Melanoma Res; 2000 Jun; 10(3):297-302. PubMed ID: 10890385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The hamster cheek pouch as a model of oral cancer for boron neutron capture therapy studies: selective delivery of boron by boronophenylalanine.
    Kreimann EL; Itoiz ME; Dagrosa A; Garavaglia R; Farías S; Batistoni D; Schwint AE
    Cancer Res; 2001 Dec; 61(24):8775-81. PubMed ID: 11751398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvement of the tumor-suppressive effect of boron neutron capture therapy for amelanotic melanoma by intratumoral injection of the tyrosinase gene.
    Morita N; Hiratsuka J; Kondoh H; Uno M; Asano T; Niki Y; Sakurai Y; Ono K; Harada T; Imajo Y
    Cancer Res; 2006 Apr; 66(7):3747-53. PubMed ID: 16585201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biodistribution of BPA and BSH after single, repeated and simultaneous administrations for neutron-capture therapy of cancer.
    Ichikawa H; Taniguchi E; Fujimoto T; Fukumori Y
    Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S111-4. PubMed ID: 19376721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preloading with L-tyrosine increases the uptake of boronophenylalanine in mouse melanoma cells.
    Papaspyrou M; Feinendegen LE; Müller-Gärtner HW
    Cancer Res; 1994 Dec; 54(24):6311-4. PubMed ID: 7987818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selectivity of boron carriers for boron neutron capture therapy: pharmacological studies with borocaptate sodium, L-boronophenylalanine and boric acid in murine tumors.
    Gregoire V; Begg AC; Huiskamp R; Verrijk R; Bartelink H
    Radiother Oncol; 1993 Apr; 27(1):46-54. PubMed ID: 8327732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A unique in vivo assessment of 4-[10B]borono-L-phenylalanine in tumour tissues for boron neutron capture therapy of malignant melanomas using positron emission tomography and 4-borono-2-[18F]fluoro-L-phenylalanine.
    Ishiwata K; Shiono M; Kubota K; Yoshino K; Hatazawa J; Ido T; Honda C; Ichihashi M; Mishima Y
    Melanoma Res; 1992 Sep; 2(3):171-9. PubMed ID: 1450671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experimental boron neutron capture therapy for melanoma: systemic delivery of boron to melanotic and amelanotic melanoma.
    Coderre JA; Glass JD; Packer S; Micca P; Greenberg D
    Pigment Cell Res; 1990 Dec; 3(6):310-8. PubMed ID: 2101931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suitability of boron carriers for BNCT: accumulation of boron in malignant and normal liver cells after treatment with BPA, BSH and BA.
    Chou FI; Chung HP; Liu HM; Chi CW; Lui WY
    Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S105-8. PubMed ID: 19375330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experimental Studies of Boronophenylalanine ((10)BPA) Biodistribution for the Individual Application of Boron Neutron Capture Therapy (BNCT) for Malignant Melanoma Treatment.
    Carpano M; Perona M; Rodriguez C; Nievas S; Olivera M; Santa Cruz GA; Brandizzi D; Cabrini R; Pisarev M; Juvenal GJ; Dagrosa MA
    Int J Radiat Oncol Biol Phys; 2015 Oct; 93(2):344-52. PubMed ID: 26232853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of boron neutron capture therapy for melanotic and amelanotic melanoma transplanted into mouse brain.
    Iwakura M; Kondoh H; Hiratsuka J; Ehara K; Tamaki N; Mishima Y
    Pigment Cell Res; 2002 Feb; 15(1):67-75. PubMed ID: 11837459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of fluorine-18-BPA-fructose for boron neutron capture treatment planning.
    Kabalka GW; Smith GT; Dyke JP; Reid WS; Longford CP; Roberts TG; Reddy NK; Buonocore E; Hübner KF
    J Nucl Med; 1997 Nov; 38(11):1762-7. PubMed ID: 9374349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutron capture therapy of intracerebral melanoma: enhanced survival and cure after blood-brain barrier opening to improve delivery of boronophenylalanine.
    Barth RF; Yang W; Bartus RT; Rotaru JH; Ferketich AK; Moeschberger ML; Nawrocky MM; Coderre JA; Rofstad EK
    Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):858-68. PubMed ID: 11849812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved survival after boron neutron capture therapy of brain tumors by Cereport-mediated blood-brain barrier modulation to enhance delivery of boronophenylalanine.
    Yang W; Barth RF; Bartus RT; Rotaru JH; Moeschberger ML; Ferketich AK; Nawrocky MM; Coderre JA; Goodman JH
    Neurosurgery; 2000 Jul; 47(1):189-97; discussion 197-8. PubMed ID: 10917362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced delivery of boronophenylalanine for neutron capture therapy of brain tumors using the bradykinin analog Cereport (Receptor-Mediated Permeabilizer-7).
    Barth RF; Yang W; Bartus RT; Moeschberger ML; Goodman JH
    Neurosurgery; 1999 Feb; 44(2):351-9; discussion 359-60. PubMed ID: 9932889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distribution of BPA and metabolic assessment in glioblastoma patients during BNCT treatment: a microdialysis study.
    Bergenheim AT; Capala J; Roslin M; Henriksson R
    J Neurooncol; 2005 Feb; 71(3):287-93. PubMed ID: 15735919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective delivery of boron by the melanin precursor analogue p-boronophenylalanine to tumors other than melanoma.
    Coderre JA; Glass JD; Fairchild RG; Micca PL; Fand I; Joel DD
    Cancer Res; 1990 Jan; 50(1):138-41. PubMed ID: 2293547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of 4-borono-2-18F-fluoro-L-phenylalanine-fructose as a probe for boron neutron capture therapy in a glioma-bearing rat model.
    Wang HE; Liao AH; Deng WP; Chang PF; Chen JC; Chen FD; Liu RS; Lee JS; Hwang JJ
    J Nucl Med; 2004 Feb; 45(2):302-8. PubMed ID: 14960653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic study of BSH and BPA in simultaneous use for BNCT.
    Yokoyama K; Miyatake S; Kajimoto Y; Kawabata S; Doi A; Yoshida T; Asano T; Kirihata M; Ono K; Kuroiwa T
    J Neurooncol; 2006 Jul; 78(3):227-32. PubMed ID: 16557351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 657.